Biopolym. Cell. 2018; 34(5):361-366.
http://dx.doi.org/10.7124/bc.00098A
Molecular Biomedicine
Study of SNRPN genetic and epigenetic mutations in Prader-Willi and Angelman patients
1Chernushyn S. Yu., 1Hryshchenko N. V.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143

Abstract

Prader-Willi (PWS) and Angelman (AS) syndromes are two clinically distinct genetic diseases associated with multiple physical and cognitive abnormalities. The genetic cause of PWS and AS is the alteration in the 15q11.2-q13 chromosomal region; expression of genes in this region is subject to genome imprinting. Aim. To analyse of the frequency of 15q11.2-q13 rearrangements and epigenetic alterations in the group of Ukrainian patients with PWS and AS. Methods. The methylation status of the SNRPN gene was analyzed by methylation-specific PCR (MS-PCR). Results. The absence of unmethylated CpGs in the SNRPN gene promoter was detected in 25 patients (42 %) with the PWS phenotype. In the AS group, the frequency of SNRPN mutations (absence of the hypermethylated CpGs) was observed in 28% of the cases. In the PWS, group we observed a significant prevalence of males (70 %), but the frequency of the confirmed diagnosis was higher in females (56% vs. 36%). A lower than expected detection rate in the PWS and AS groups could be due to both clinical and method limitations. Conclusions. Analysis of the SRNPN gene region by MS-PCR could be used for the PWS and AS molecular diagnostics. This test can rule out the clinical diagnosis of PWS in ~ 60 % of Ukrainian patients with suspected PWS and confirm AS in ~30% of patients.
Keywords: Prader-Willi Syndrome, Angelman Syndrome, SNRPN gene, methyl-specific PCR.
Full text: (PDF, in English)

References

[1] Kalsner L, Chamberlain SJ. Prader-Willi, Angelman, and 15q11-q13 Duplication Syndromes. Pediatr Clin North Am. 2015;62(3):587-606.
[2] Choufani S, Weksberg R. Genomic imprinting. Funct Nucl 2016; 4(1): 449–65.
[3] Sharp AJ, Migliavacca E, Dupre Y, Stathaki E, Sailani MR, Baumer A, Schinzel A, Mackay DJ, Robinson DO, Cobellis G, Cobellis L, Brunner HG, Steiner B, Antonarakis SE. Methylation profiling in individuals with uniparental disomy identifies novel differentially methylated regions on chromosome 15. Genome Res. 2010;20(9):1271-8.
[4] LaSalle JM, Reiter LT, Chamberlain SJ. Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders. Epigenomics. 2015;7(7):1213-28.
[5] Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70-3.
[6] Ramsden SC, Clayton-Smith J, Birch R, Buiting K. Practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes. BMC Med Genet. 2010;11:70.
[7] Smith A, Robson L, St Heaps L. Use of two FISH probes provides a cost-effective, simple protocol to exclude an imprinting centre defect in routine laboratory testing for suspected Prader-Willi and Angelman syndrome. Ann Genet. 2002;45(4):189-91.
[8] Elsheikh BH, Kissel JT. Spinal Muscular Atrophies. In: Eds. Katirji B., Kaminski H., Ruff R. Neuromuscular Disorders in Clinical Practice. Springer, New York, NY;2014:425–39.
[9] Puiu M, Cucu N. Prader – Willi Syndrome, from Molecular Testing and Clinical Study to Diagnostic Protocols. Rijeka: "InTech", 2011; 472 p.
[10] Watson P, Black G, Ramsden S, Barrow M, Super M, Kerr B, Clayton-Smith J. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J Med Genet. 2001;38(4):224-8.
[11] Hitchins MP, Rickard S, Dhalla F, Fairbrother UL, de Vries BB, Winter R, Pembrey ME, Malcolm S. Investigation of UBE3A and MECP2 in Angelman syndrome (AS) and patients with features of AS. Am J Med Genet A. 2004;125A(2):167-72.